Skip to main content
Year archive

IMMUTEP LIMITED — 2022 filings

All 84 regulatory filings released by IMMUTEP LIMITED (IMM) in 2022, sourced directly from the official regulator.

84 Filings
2022 Period
2022 filings (84)
Filing Released Lang
Update on MBC trial design following successful FDA meeting 3 pages 226.1KB
Capital/Financing Update
2022-12-22 English
Change of Director's Interest Notice - R Howard 3 pages 220.9KB
Director's Dealing
2022-12-21 English
Change of Director's Interest Notice - P Meyers 3 pages 225.6KB
Director's Dealing
2022-12-21 English
Change of Director's Interest Notice L Turnbull 3 pages 233.0KB
Director's Dealing
2022-12-21 English
Application for quotation of securities - IMM 6 pages 27.8KB
Share Issue/Capital Change
2022-12-20 English
Notification regarding unquoted securities - IMM 5 pages 26.7KB
Share Issue/Capital Change
2022-12-15 English
Notification regarding unquoted securities - IMM 5 pages 26.7KB
Share Issue/Capital Change
2022-12-15 English
Proposed issue of securities - IMM 5 pages 28.1KB
Capital/Financing Update
2022-12-14 English
Commercial Scale in Manufacturing of Efti Achieved 2 pages 271.1KB
Capital/Financing Update
2022-12-07 English
GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist 2 pages 287.0KB
Capital/Financing Update
2022-12-05 English
Immutep enters 2nd collaboration with Pfizer and Merck KGaA 3 pages 231.4KB
Capital/Financing Update
2022-11-28 English
Immutep AGM 2022 - Chairman's Address 3 pages 216.4KB
AGM Information
2022-11-22 English
Immutep AGM 2022 - CEO's Presentation 22 pages 3.0MB
AGM Information
2022-11-22 English
Results of Meeting 2 pages 268.7KB
Declaration of Voting Results & Voting Rights Announcements
2022-11-22 English
Immutep Investor Update 11 pages 705.3KB
Investor Presentation
2022-11-16 English
Immutep receives A$1 million R&D Tax Incentive 1 pa
Capital/Financing Update
2022-11-13 English
INSIGHT-003 triple combination data presented at SITC 2022 3 pages 301.4KB
Regulatory Filings
2022-11-10 English
TACTI-002 data presented at SITC for Efti in 1st line NSCLC 6 pages 499.3KB
Capital/Financing Update
2022-11-10 English
Immutep Webcast to discuss clinical data presented at SITC 25 pages 2.3MB
Investor Presentation
2022-11-10 English
New Patents Granted in Japan and South Korea for Efti 2 pages 218.7KB
Regulatory Filings
2022-11-08 English
Abstract for Efti selected for SITC 2022 Press Conference 2 pages 274.6KB
Regulatory Filings
2022-11-03 English
Late Breaking Abstract accepted for SITC Oral Presentation 2 pages 209.7KB
Investor Presentation
2022-11-02 English
Immutep to Participate in Two Upcoming Investor Conferences 1
Investor Presentation
2022-11-01 English
Immutep Corporate Presentation 30 pages 3.3MB
Investor Presentation
2022-11-01 English
Annual Report filed on Form 20-F with SEC 147 pages 719.5KB
Annual Report
2022-10-31 English
Independent DMC recommends to continue TACTI-003 as planned 3 pages 226.9KB
Regulatory Filings
2022-10-25 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 450.6KB
Interim / Quarterly Report
2022-10-24 English
Annual Report to shareholders 84 pages 1.2MB
Annual Report
2022-10-20 English
Appendix 4G and Corporate Governance Statement 37 pages 522.8KB
Governance Information
2022-10-20 English
Notice of Annual General Meeting/Proxy Form 22 pages 2.1MB
AGM Information
2022-10-20 English
Change in substantial holding 6 pages 1.6MB
Major Shareholding Notification
2022-10-17 English
Application for quotation of securities - IMM 6 pages 27.8KB
Capital/Financing Update
2022-10-12 English
Abstracts accepted for Presentation at SITC 2022 2 pages 289.5KB
Regulatory Filings
2022-10-05 English
Change of Director's Interest Notice - F Triebel 3 pages 217.3KB
Director's Dealing
2022-10-04 English
Change of Director's Interest Notice - M Voigt 3 pages 223.4KB
Director's Dealing
2022-10-04 English
Change of Director's Interest Notice - P Meyers 3 pages 230.3KB
Director's Dealing
2022-10-04 English
Fast Track granted by US FDA for Efti in 1st line NSCLC 2 pages 229.5KB
Capital/Financing Update
2022-10-03 English
Application for quotation of securities - IMM 6 pages 28.9KB
Share Issue/Capital Change
2022-10-02 English
Immutep to Participate in Two Upcoming Investor Conferences 2 pages 204.5KB
Regulatory Filings
2022-09-25 English
Immutep Receives A$2.7 million R&D French Tax Incentive 2 pages 225.5KB
Capital/Financing Update
2022-09-22 English
2022 AGM & Key Dates 1 page 209.2KB
AGM Information
2022-09-20 English
Clinical Development Update for Eftilagimod Alpha 3 pages 274.1KB
Regulatory Filings
2022-09-13 English
Immutep Appoints LAG-3 Pioneer Dr Frederic Triebel to Board 2 pages 211.7KB
Board/Management Information
2022-09-12 English
Initial Director's Interest Notice - Frederic Triebel 2 pages 167.9KB
Director's Dealing
2022-09-12 English
New investigator-initiated ph2 trial in Soft Tissue Sarcoma 3 pages 272.4KB
Regulatory Filings
2022-09-05 English
Appendix 4E & 2022 Full Year Statutory Accounts 87 pages 1.5MB
Regulatory Filings
2022-08-30 English
Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1 2 pages 206.6KB
Regulatory Filings
2022-08-29 English
TACTI-002 2nd line lung cancer data presented at 2022 WCLC 4 pages 348.0KB
Interim / Quarterly Report
2022-07-31 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 505.1KB
Interim / Quarterly Report
2022-07-27 English
Notification of cessation of securities - IMM 4 pages 24.3KB
Regulatory Filings
2022-07-13 English
Immutep granted Japanese Patent for IMP761 2 pages 213.3KB
Regulatory Filings
2022-07-05 English
TACTI-002 lung cancer data to be presented at 2022 WCLC 2 pages 280.8KB
Regulatory Filings
2022-06-26 English
Immutep Investor Update 7 pages 678.2KB
Investor Presentation
2022-06-16 English
Positive ORR in 1st line NSCLC from ph 2 TACTI-002 trial 5 pages 398.3KB
Regulatory Filings
2022-06-05 English
Webcast slides for 1st line NSCLC data from TACTI-002 trial 27 pages 1.1MB
Investor Presentation
2022-06-05 English
Immutep webcast for TACTI-002 data presented at ASCO 2022 2 pages 225.1KB
Regulatory Filings
2022-06-01 English
Immutep announces publication of ASCO 2022 abstracts 2 pages 277.5KB
Regulatory Filings
2022-05-26 English
Immutep Corporate Presentation 35 pages 1.6MB
Investor Presentation
2022-05-23 English
Immutep to Present at Investor Conferences 2 pages 219.1KB
Investor Presentation
2022-05-19 English
Leading Oncologists appointed to Clinical Advisory Board 3 pages 217.4KB
Board/Management Information
2022-05-17 English
New & significant data from AIPAC phase 2b trial in MBC 4 pages 303.6KB
Regulatory Filings
2022-05-03 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 523.1KB
Interim / Quarterly Report
2022-04-28 English
Immutep to announce new TACTI-002 data at ASCO 2022 2 pages 288.4KB
Regulatory Filings
2022-04-27 English
Change in substantial holding 6 pages 1.3MB
Major Shareholding Notification
2022-04-07 English
Efti with Keytruda shows encouraging activity in lung cancer 4 pages 327.5KB
Capital/Financing Update
2022-03-29 English
Immutep announces publication of ELCC 2022 abstract 2 pages 278.9KB
Regulatory Filings
2022-03-23 English
Japanese patent granted for LAG-3 antibody LAG525 2 pages 217.1KB
Regulatory Filings
2022-03-17 English
Immutep to present Phase IIb breast cancer data at ESMO 2022 2 pages 258.9KB
Regulatory Filings
2022-03-17 English
Change in substantial holding 6 pages 924.6KB
Major Shareholding Notification
2022-03-15 English
Application for quotation of securities - IMM 6 pages 27.8KB
Share Issue/Capital Change
2022-03-10 English
Immutep receives FDA feedback for Efti development in MBC 2 pages 213.9KB
Regulatory Filings
2022-03-09 English
Appointment of Non-Executive Director 2 pages 202.0KB
Board/Management Information
2022-02-24 English
Proposed issue of securities - IMM 5 pages 27.8KB
Capital/Financing Update
2022-02-24 English
Initial Director's Interest Notice - Lucy Turnbull 3 pages 226.6KB
Director's Dealing
2022-02-24 English
Immutep to Present at Healthcare Investor Conferences 2 pages 217.2KB
Investor Presentation
2022-02-23 English
Half Yearly Report and Accounts 30 pages 496.3KB
Interim / Quarterly Report
2022-02-22 English
Immutep Investor Update 13 pages 1.2MB
Investor Presentation
2022-02-17 English
Immutep to present new data from TACTI-002 at ELCC 2022 2 pages 259.7KB
Investor Presentation
2022-02-17 English
Australian Patent Granted for Efti with PD-1 Inhibitors 2 pages 226.3KB
Regulatory Filings
2022-02-10 English
Death of Director Grant Chamberlain 3 pages 459.8KB
Board/Management Information
2022-02-01 English
Change in substantial holding 6 pages 1.3MB
Major Shareholding Notification
2022-02-01 English
Immutep to present at February Investor Conferences 2 pages 224.8KB
Investor Presentation
2022-01-30 English
Immutep Quarterly Activities Report and Appendix 4C 9 pages 518.3KB
Interim / Quarterly Report
2022-01-24 English
Change in substantial holding 6 pages 920.9KB
Major Shareholding Notification
2022-01-04 English